Quarterly report · Q2
9265.TEDINET S100PWJZ
Period2022-06-01 → 2022-11-30
Filed2023-01-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥27.7bn | 2022-06-01 → 2022-11-30 | Cons. | Net sales |
| Revenue | ¥55.1bn | 2021-06-01 → 2022-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥27.3bn | 2021-06-01 → 2021-11-30 | Cons. | Net sales |
| Operating income | ¥598m | 2022-06-01 → 2022-11-30 | Cons. | Operating income |
| Operating income | ¥663m | 2021-06-01 → 2021-11-30 | Cons. | Operating income |
| Ordinary income | ¥624m | 2022-06-01 → 2022-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2021-06-01 → 2022-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥701m | 2021-06-01 → 2021-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥20m | 2022-06-01 → 2022-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥713m | 2021-06-01 → 2021-11-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥201m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥696m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥471m | 2021-06-01 → 2021-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥204m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss |
| Net income | ¥471m | 2021-06-01 → 2021-11-30 | Cons. | Profit loss |
| Total assets | ¥22.9bn | at 2022-11-30 | Cons. | Assets |
| Total assets | ¥24.1bn | at 2022-05-31 | Cons. | Assets |
| Total assets | ¥25.1bn | at 2021-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥15.3bn | at 2022-11-30 | Cons. | Liabilities |
| Total liabilities | ¥16.1bn | at 2022-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.6bn | at 2022-11-30 | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2022-05-31 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2021-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.8bn | at 2022-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.0bn | at 2022-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2022-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2022-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2021-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2021-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥1.9bn | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥581m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥751m | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥88m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥27m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥318m | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥209m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥229m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥229m | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-78.98 | 2022-06-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-143.68 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥272.67 | 2021-06-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥184.81 | 2021-06-01 → 2021-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥128.29 | 2021-09-01 → 2021-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 33.2% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.3% | at 2021-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2022-11-30 | −¥11m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2022-11-30 | −¥11m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2022-11-30 | −¥447m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥140m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥140m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥3m |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥27.5bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥27.5bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥11m |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥1.0bn |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥33m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥33m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥0 |
| —segment total | revenue | 2022-06-01 → 2022-11-30 | ¥27.7bn |
| —segment total | revenue external | 2022-06-01 → 2022-11-30 | ¥27.7bn |
| —segment total | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥11m |
| —segment total | segment profit | 2022-06-01 → 2022-11-30 | ¥1.0bn |
| Reconciling Itemsreconciling | revenue | 2021-06-01 → 2021-11-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2021-06-01 → 2021-11-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2021-06-01 → 2021-11-30 | −¥415m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue | 2021-06-01 → 2021-11-30 | ¥136m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2021-06-01 → 2021-11-30 | ¥136m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2021-06-01 → 2021-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2021-06-01 → 2021-11-30 | ¥3m |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue | 2021-06-01 → 2021-11-30 | ¥27.2bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue external | 2021-06-01 → 2021-11-30 | ¥27.2bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue intersegment | 2021-06-01 → 2021-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | segment profit | 2021-06-01 → 2021-11-30 | ¥1.1bn |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue | 2021-06-01 → 2021-11-30 | ¥34m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue external | 2021-06-01 → 2021-11-30 | ¥34m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | segment profit | 2021-06-01 → 2021-11-30 | ¥0 |
| —segment total | revenue | 2021-06-01 → 2021-11-30 | ¥27.3bn |
| —segment total | revenue external | 2021-06-01 → 2021-11-30 | ¥27.3bn |
| —segment total | revenue intersegment | 2021-06-01 → 2021-11-30 | ¥0 |
| —segment total | segment profit | 2021-06-01 → 2021-11-30 | ¥1.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 487
| Item | Context | Value | Unit |
|---|---|---|---|
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 499000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | -188000000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | － | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | -2000000 | JPY |
| Income before income taxes | Prior1YTDDuration | 713000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 20000000 | JPY |
| Depreciation and amortization ope cf | Prior1YTDDuration | 92000000 | JPY |
| Depreciation and amortization ope cf | CurrentYTDDuration | 94000000 | JPY |
| Amortization of goodwill ope cf | Prior1YTDDuration | 15000000 | JPY |
| Amortization of goodwill ope cf | CurrentYTDDuration | 7000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1YTDDuration | 1000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYTDDuration | 612000000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1YTDDuration | -445000000 | JPY |
| Increase decrease in provision for bonuses ope cf | CurrentYTDDuration | -443000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1YTDDuration | -40000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYTDDuration | 0 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -5000000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -5000000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 1000000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 1000000 | JPY |
| Receipts from contingent consideration ope cf | Prior1YTDDuration | -8000000 | JPY |
| Receipts from contingent consideration ope cf | CurrentYTDDuration | -6000000 | JPY |
| Loss gain on step acquisitions ope cf | Prior1YTDDuration | -4000000 | JPY |
| Loss gain on step acquisitions ope cf | CurrentYTDDuration | － | JPY |
| Equity in earnings losses of affiliates ope cf | Prior1YTDDuration | -10000000 | JPY |
| Equity in earnings losses of affiliates ope cf | CurrentYTDDuration | － | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | -1874000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | -459000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -7000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | -539000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | 1173000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | -52000000 | JPY |
| Decrease increase in claims provable in bankruptcy claims provable in rehabilitation ope cf | Prior1YTDDuration | － | JPY |
| Decrease increase in claims provable in bankruptcy claims provable in rehabilitation ope cf | CurrentYTDDuration | -611000000 | JPY |
| Other net ope cf | Prior1YTDDuration | -107000000 | JPY |
| Other net ope cf | CurrentYTDDuration | -340000000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | -504000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | -1723000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 54000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 5000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -1000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -1000000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -308000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -145000000 | JPY |
| Income taxes refund ope cf | Prior1YTDDuration | 8000000 | JPY |
| Income taxes refund ope cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | -751000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | -1865000000 | JPY |
| Proceeds from contingent consideration inv cf | Prior1YTDDuration | 8000000 | JPY |
| Proceeds from contingent consideration inv cf | CurrentYTDDuration | 6000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |